Skip to Main Content

Hello, everyone, and how are you today? We are doing just fine, despite a menacing tuft of gray clouds hovering over the Pharmalot campus. After all, why not look on the sunny side? Meanwhile, please join us for a delicious cup or three of stimulation — our flavor today is cinnamon vanilla nut, for those who track this sort of thing. Feel free to join us, in any event. Remember, no prescription is required. Meanwhile, here are some tidbits. Have a lovely day and do stay in touch …

The California Senate voted in favor of a drug pricing transparency bill, which now goes to Gov. Jerry Brown. The bill has been vociferously fought by the pharmaceutical industry and could become one of the most comprehensive state efforts to address pricing transparency. Drug makers would have to provide 60-day notice to insurers and government health plans before increasing list prices of medicines by 16 percent in a two-year period.


A Food and Drug Administration advisory panel voted unanimously to recommended that a shingles vaccine from GlaxoSmithKline (GSK) be approved to treat adults aged 50 and over, Reuters reports. The Shingrix vaccine is considered one of the more important products in the Glaxo pipeline, with annual sales forecast to reach $1 billion by 2023. Merck’s Zostavax, which was approved in 2006, is expected to generate sales of $730 million this year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!